Agenus Inc.

Emmanuel Cyrille Pascal Briend

Olga Ignatovich

Benjamin Maxime Morin

Dhan Sidhartha Chand

K Mark Bushell

Nicola Anne Ramsay

Spencer Campbell

Nicholas Stuart Wilson

Oliver Schon

Jeremy Dale Waight

Shawn Michael Jennings

Randi Barbara Gombos

Zahra Jawad

Beth Wensley

Veronica Franciszka Ilkow

The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.

Anti-TIGIT and anti-CD96 antibodies

The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF&#x3b2;-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-CD73 antibodies and methods of use thereof

The instant disclosure provides antibodies that specifically bind to CD96 (e.g., human CD96) and antagonize CD96 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Antibodies that specifically bind human CD96

Growing community of inventors

Cambridge, United Kingdom

Emmanuel Cyrille Pascal Briend